These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 22804749)

  • 1. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
    Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
    Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T; Kasai H; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy.
    Kraff S; Nieuweboer AJ; Mathijssen RH; Baty F; de Graan AJ; van Schaik RH; Jaehde U; Joerger M
    Cancer Chemother Pharmacol; 2015 May; 75(5):975-83. PubMed ID: 25761456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
    Kraff S; Lindauer A; Joerger M; Salamone SJ; Jaehde U
    Ther Drug Monit; 2015 Dec; 37(6):725-32. PubMed ID: 25774704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
    Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.
    Chen N; Li Y; Ye Y; Palmisano M; Chopra R; Zhou S
    J Clin Pharmacol; 2014 Oct; 54(10):1097-107. PubMed ID: 24719309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
    Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
    Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.
    Joerger M; Huitema AD; van den Bongard DH; Schellens JH; Beijnen JH
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2150-7. PubMed ID: 16609028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
    Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.
    Mendes MS; Hatley O; Gill KL; Yeo KR; Ke AB
    Eur J Pharm Sci; 2020 Jul; 150():105355. PubMed ID: 32438273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
    Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
    J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
    Smorenburg CH; Sparreboom A; Bontenbal M; Stoter G; Nooter K; Verweij J
    J Clin Oncol; 2003 Jan; 21(2):197-202. PubMed ID: 12525510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.
    Fetterly GJ; Tamburlin JM; Straubinger RM
    Biopharm Drug Dispos; 2001 Sep; 22(6):251-61. PubMed ID: 11754041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.
    Chi KN; Chia SK; Dixon R; Newman MJ; Wacher VJ; Sikic B; Gelmon KA
    Invest New Drugs; 2005 Aug; 23(4):311-5. PubMed ID: 16012790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer.
    Gota V; Nookala M; Bonda A; Karanam A; Shriyan B; Kembhavi Y; Gurjar M; Patil A; Singh A; Goyal N; Gupta S
    Cancer Med; 2021 May; 10(9):3068-3076. PubMed ID: 33826243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
    Crombag MBS; Koolen SLW; Wijngaard S; Joerger M; Dorlo TPC; van Erp NP; Mathijssen RHJ; Beijnen JH; Huitema ADR
    Pharm Res; 2019 Oct; 36(12):163. PubMed ID: 31617004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.